MedTech Dive April 8, 2024
Nick Paul Taylor

Physicians said the test is based “on old genetic studies that have largely been abandoned” and could exacerbate the opioid crisis.

Dive Brief:

  • Physicians asked the Food and Drug Administration Thursday to revoke its recent approval of Autogenomics’ AvertD genetic test for opioid addiction.
  • The Physicians for Responsible Opioid Prescribing (PROP) said the test is based “on old genetic studies that have largely been abandoned.” They said the test could exacerbate the opioid crisis by leading to overprescribing in patients who falsely test negative, or could wrongly label people as prone to opioid use disorder, causing them to face discrimination or not receive treatment.
  • PROP sent another letter to the Centers for Medicare and Medicaid Services (CMS). Quoting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Physician, Provider
Related Articles:
109 hospitals receiving new Medicare-backed residency slots
STAT+: UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits
AI Robot Scanner as Good as Rheumatologists at Assessing RA
Senators urge Congress to avert Medicare physician pay cut
New study offers insights into reliable Alzheimer's diagnosis

Share This Article